Blend Labs is unappealing because its business shows stalling growth, growing churn and a shrinking cash pile. The chart is a falling knife without signs of life, and Lemonade is the better place to stay than adding Blend. x.com
Dr J Rould
Full-Time Tech Investor, Quantum/Cybersecurity, Philosophy Background
Lemonade looks good but not good enough after a lofty price and high expectations into earnings, so it needs to get cheaper before it is worth buying. In-force premium grew 32% and revenue 79% as it approaches positive cash flow by the end of 2026; the low $40s or $30s would be the level to buy more. x.com x.com
Lemonade's business thesis has not broken; the stock is falling on normal high-beta behavior, not fundamentals. With beta over two, high short interest and no profits yet, it moves sharply with risk appetite. Co-founder Daniel Schreiber's share sales are normal for a founder with concentrated wealth, though their framing was tone deaf, and stock pay is needed to hire engineers against Google and Meta. Long-term holders should watch in-force premium growth, loss ratio and operating leverage. … Show more
Lemonade's cash burn makes its promotion by paid influencers on X suspect. Its shares are down 38% year to date, alongside other heavily promoted stocks. x.com
Lemonade looks expensive once valued as what it is, an insurance company. Replying to @javierluraschi's post on the stock, any price above 1x revenue is expensive for an insurer. x.com
Self-driving cars give Root and Lemonade no edge, because if accidents fall, everyone benefits and insurers charge less, so the whole auto insurance industry shrinks. On the surface the risk looks like self-driving's threat to Uber, but the mechanics are completely different, and insurance companies are not attractive to own in general. The view is offered tentatively, as a non-expert. x.com x.com
Root is cheap and could be a better buy than Lemonade here, because it is proving it can grow and make money at the same time. It picked the difficult personal auto market and executed exceptionally, with underwriting improving quarter after quarter and capital-efficient scaling showing up as high ROIC. The market will likely reward that. The choice versus Lemonade, which is building a long-term insurance brand, remains nuanced and depends on what an investor wants. x.com
Lemonade's share-price drop after a great second quarter is a wild overreaction. Per its Q2 2026 results, in-force premium rose 32.4% to $1.43 billion and revenue grew 79% to $294 million, the 11th straight quarter of accelerating growth, with over 3.3 million customers. x.com x.com
SiTime, Tempus AI and Lemonade look like AI beneficiaries that need not rely on rising frontier-model spending, unlike a crowded trade vulnerable to concentrated capital and circular financing. SiTime can expand into robotics even if data-center growth slows; clinical decisions still need Tempus; Lemonade's models may improve loss ratios and retention while lower compute costs could help it. x.com
Lemonade will likely fall back below $60 again, as it usually does, because it does not expect to be profitable until late 2027–2028, which keeps the stock volatile for a while. x.com
Lemonade is a monster stock in the making after a massive quarter. Per co-founder @shai_wininger, in-force premium grew 32% to $1.33 billion, the 10th straight quarter of acceleration, revenue rose 71% to $258M and gross profit 159% to $100M, with $17M of adjusted free cash flow. Pet passed $500M of premium, car grew 60% with its loss ratio down 14 points to 74%, and Lemonade raised 2026 guidance, targeting positive adjusted EBITDA in Q4. x.com